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ABSTRACT 
 
Introduction: Tumours of ovary are common form neoplasms in 
women. Diverse histopathologies are common in ovarian tumours 
reflecting the different cells origins of tumours. Determination of various 
histological patterns of ovarian tumours is very important in diagnosis as 
well as prognosis of ovarian tumours. 
 Aims: The study is to determine the histopathological patterns of 
ovarian neoplasms and to show the distribution of age, residency, risk 
factors and clinical presentation in Sudanese females.  
Methodology: This is descriptive a retrospective study conducted on 
Sudanese females in the period from January 2009 to through January 
2010 at the National Health Laboratory and Khartoum Teaching Hospital. 
The slides were done from tissue fixed in 10% formalin for 24 hours or 
more, handled according to histological protocol, embedded in paraffin 
wax, sectioned by microtome of 3-5mm thickness of sections, and stained 
by hematoxylin and eosin stain.   
Results: One hundred and forty three patients with ovarian 
neoplasms were included in the study. The commonest age group was 21- 
30 years and the age for all patients range between 9-80 years. Ovarian 
neoplasms showed some geographical variation in Sudan. The majority of 
these cases were from Western and Northern regions. The most common 
symptoms were lower abdominal pain and abdominal enlargement. One 
hundred and eleven of the ovarian tumours (77.6%) are benign, and 
(22.4%) 32/143 are malignant. Surface epithelial stromal tumours were the 
most common 75/143 (52.4%), followed by the germ cell tumour 52/143 
 
 
(36.4%). Mature cystic teratoma was the most benign tumour 
46/111(41.4%), followed by serous cyst adenoma 44/111 (39.7%). Serous 
adenocarcinoma was the commonest malignant tumour 8/32 (25.0%), 
followed by granulosa cell tumour 7/32 (21.9%). For all age groups the 
benign tumours were more than malignant ones, the most benign ovarian 
tumours (38.2%) were seen in the age group 21-30 years but the most 
malignant tumours occurred above 40 years (51.6%).  
Conclusion: This study concluded that, the benign tumours were more 
common than malignant ones for all age groups.  The age of most ovarian 
tumours were between 21 – 30 years old. Surface epithelial tumours were 
most common class of ovarian tumours, where germ cell tumours were 
next to it. Benign surface epithelial tumours being most common benign 
tumours and malignant ones being most malignant tumours. Considering 
individual tumours, mature cystic teratoma was the most common ovarian 
tumours overall, as well as most common benign tumour followed by 
serous cyst adenoma. Serous cyst adenocarcinoma was most common 
malignancy, followed by granulosa cell tumours.  Malignant ovarian 
tumours were more common above 40 years. The presenting symptoms 
were lower abdominal pain and abdominal enlargement.   
Recommendations:  Further in depth studies are highly recommended 
to be carried out for more evaluation of risk factors and find out the cause 
of high rate of the disease in this country. For unnecessary removal of the 
ovary, frozen section is recommended. Improvement of the cancer 
reporting and registration activity. Detailed histopathological diagnosis, 
grading and staging.    
 
  
 
 
  ﺍﻟﻤﺴﺘﺨﻠﺹ
 
ﺇﺨﺘﻼﻑ ﺍﻟﺘﺸﺭﻴﺢ ﺍﻟﻤﺭﻀﻰ ﺍﻟﻨﺴﻴﺠﻲ ﺸﺎﺌﻊ . ﺃﻭﺭﺍﻡ ﺍﻟﻤﺒﻴﺽ ﺃﻜﺜﺭ ﺸﻴﻭﻋﺎﹰ ﺒﻴﻥ ﺍﻟﻨﺴﺎﺀ: ﺍﻟﻤﻘﺩﻤﺔ
ﺘﺤﺩﻴﺩ ﺍﻟﻨﻤﻁ ﺍﻟﻨﺴﻴﺠﻲ ﺍﻟﻤﺨﺘﻠﻑ ﺫﻭ . ﺘﻼﻑ ﺃﺼل ﺍﻟﺨﻠﻴﺔ ﺍﻟﻭﺭﻤﻴﺔﻓﻲ ﺃﻭﺭﺍﻡ ﺍﻟﻤﺒﻴﺽ ﻭﺫﻟﻙ ﻴﻌﻜﺱ ﺇﺨ
  .  ﺃﻫﻤﻴﺔ ﻓﻲ ﺍﻟﺘﺸﺨﻴﺹ ﻭﺍﻹﻨﺫﺍﺭ
ﻫﺩﻓﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺇﻟﻰ ﺘﺤﺩﻴﺩ ﺍﻟﻨﻤﻁ ﺍﻟﻨﺴﻴﺠﻲ ﺍﻟﻤﺭﻀﻲ ﻷﻭﺭﺍﻡ ﺍﻟﻤﺒﻴﺽ ﻭﺘﻭﻀﻴﺢ : ﺍﻷﻫﺩﺍﻑ
  . ﺍﻟﻌﻼﻤﺎﺕ ﺍﻟﺴﺭﻴﺭﻴﺔﻭﺘﻭﺯﻴﻊ ﻜل ﻤﻥ ﺍﻟﻌﻤﺭ ﻭﺍﻷﺼل ﻭﻋﻭﺍﻤل ﺍﻟﺨﻁﻭﺭﺓ 
ﻤﺭﺠﻌﻴﺔ ﺍﺠﺭﻴﺕ ﻋﻠﻰ ﻨﺴﺎﺀ ﺴﻭﺩﺍﻨﻴﺎﺕ ﻓﻲ ﺍﻟﻔﺘﺭﺓ ﻤﻥ  ﺍﺴﺘﻌﺎﺩﻴﺔ ﻫﺫﻩ ﺩﺭﺍﺴﺔ :ﻤﻨﻬﺠﻴﺔ ﺍﻟﺒﺤﺙ
ﺍﻟﺨﺭﻁﻭﻡ ﻭ ﻤﺴﺘﺸﻔﻰ  –ﻡ ﻓﻲ ﻜل ﻤﻥ ﺍﻟﻤﻌﻤل ﺍﻟﻘﻭﻤﻲ ﺍﻟﺼﺤﻲ 0102ﻡ ﺇﻟﻰ ﻴﻨﺎﻴﺭ  9002ﻴﻨﺎﻴﺭ 
ﻡ ﺜﺴﺎﻋﺔ ﺃﻭ ﺃﻜﺜﺭ ﻭ 42ﻓﻭﺭﻤﺎﻟﻴﻥ ﻟﻤﺩﺓ % 01ﺘﻡ ﺘﺠﻬﻴﺯ ﺍﻟﺸﺭﺍﺌﺢ ﺒﻐﻤﺭﻫﺎ ﻓﻲ . ﺍﻟﺨﺭﻁﻭﻡ ﺍﻟﺘﻌﻠﻴﻤﻲ
ﻲ ﺸﻤﻊ ﺍﻟﺒﺭﺒﺎﻓﻴﻥ، ﺜﻡ ﻗﻁﻌﺕ ﺒﻭﺍﺴﻁﺔ ﻓ ﺘﻤﺕ ﻤﻌﺎﻟﺠﺘﻬﺎ ﻨﺴﻴﺠﻴﺎﹰ ﺤﺴﺏ ﺍﻟﺒﺭﻭﺘﻭﻜﻭل ﺍﻟﻨﺴﻴﺠﻲ، ﻏﻤﺭﺕ
  .  ﻤﻠﻡ ﻟﻜل ﻗﻁﺎﻉ، ﺜﻡ ﺼﺒﻐﺕ ﺒﺼﺒﻐﺔ ﺍﻟﻬﻴﻤﺎﺘﻭﻜﺴﻠﻴﻥ ﻭﺍﻹﻴﻭﺴﻴﻥ 5- 3ﺠﻬﺎﺯ ﺍﻟﻤﻴﻜﺭﻭﺘﻭﻡ ﺒﺴﻤﻙ 
ﺴﻨﺔ، ﻭﻜﺎﻨﺕ  08- 9ﻤﺎ ﺒﻴﻥ  ﺍﻋﻤﺎﺭﻫﻡﻤﺭﻴﻀﺔ، ﺘﺭﺍﻭﺤﺕ  341ﺸﻤﻠﺕ ﺍﻟﺩﺭﺍﺴﺔ  :ﺍﻟﻨﺘﺎﺌﺞ 
. ﻥ، ﺜﻡ ﺍﻟﺸﻤﺎلﺴﻨﺔ، ﻭﺍﻜﺜﺭ ﺍﻟﺤﺎﻻﺕ ﻤﻥ ﻤﻨﻁﻘﺔ ﻏﺭﺏ ﺍﻟﺴﻭﺩﺍ 03-12ﺍﻟﻔﺌﺔ ﺍﻟﻌﻤﺭﻴﺔ ﺍﻷﻜﺜﺭ ﺸﻴﻭﻋﺎﹰ 
ﺤﺎﻟﺔ ﻤﻥ  111ﺃﻭﻀﺤﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺃﻥ ﺃﻫﻡ ﺍﻷﻋﺭﺍﺽ ﺘﺘﻤﺜل ﻓﻲ ﺃﻟﻡ ﺃﺴﻔل ﺍﻟﺒﻁﻥ ﻭﺘﻭﺭﻡ ﺍﻟﺒﻁﻥ، 
ﺃﻭﺭﺍﻡ ﺨﺒﻴﺜﻪ، ﺍﻟﻭﺭﻡ ﺍﻟﻅﻬﺎﺭﻱ %(  4.22) 341/23ﺃﻭﺭﺍﻡ ﺤﻤﻴﺩﺓ ﻭ%(  6.77)ﺃﻭﺭﺍﻡ ﺍﻟﻤﺒﻴﺽ 
، ﺍﻟﻭﺭﻡ ﺍﻟﻤﺴﺨﻲ %(4.63) 341/25، ﻴﻠﻴﻪ ﻭﺭﻡ ﺍﻟﺨﻠﻴﺔ ﺍﻟﺘﻨﺎﺴﻠﻴﺔ %(4.25) 341/57ﺍﻟﺴﻁﺤﻲ   
، ﻴﻠﻴﻪ ﺍﻟﻭﺭﻡ ﺍﻟﻐﺩﻱ ﺍﻟﻤﺼﻠﻲ %(4.14) 111/64ﺍﻟﻨﺎﻀﺞ ﺍﻜﺜﺭ ﺸﻴﻭﻋﺎﹰ ﺒﻴﻥ ﺍﻷﻭﺭﺍﻡ ﺍﻟﺤﻤﻴﺩﺓ  ﺍﻟﻜﻴﺴﻲ
 23/8ﺍﻟﻭﺭﻡ ﺍﻟﻐﺩﻱ ﺍﻟﺴﺭﻁﺎﻨﻲ ﺍﻟﻤﺼﻠﻲ ﺍﻜﺜﺭ ﺸﻴﻭﻋﺎﹰ ﺒﻴﻥ ﺍﻷﻭﺭﺍﻡ ﺍﻟﺨﺒﻴﺜﺔ  %(. 7.93) 111/44
ﺍﻷﻭﺭﺍﻡ ﺍﻟﺤﻤﻴﺩﺓ ﺃﻜﺜﺭ ﺸﻴﻭﻋﺎﹰ ﺒﻴﻥ ﺍﻟﻔﺌﺔ %(. 9.12) 23/7، ﻴﻠﻴﻪ ﻭﺭﻡ ﺍﻟﺨﻠﻴﺔ ﺍﻟﻤﺤﺒﺒﻪ %(0.52)
ﺒﻴﻨﻤﺎ ﺍﻷﻭﺭﺍﻡ ﺍﻟﺨﺒﻴﺜﺔ ﺃﻜﺜﺭ ﺸﻴﻭﻋﺎﹰ ﻓﻲ ﺍﻟﻔﺌﺔ ﺍﻟﻌﻤﺭﻴﺔ ﻤﺎ ﻓﻭﻕ %( 2.83)ﺴﻨﺔ ( 03- 12)ﺍﻟﻌﻤﺭﻴﺔ 
  %(.6.15)ﺴﻨﺔ  04ﺍﻟـ
ﺨﻠﺼﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺇﻟﻰ ﺃﻥ ﺃﻭﺭﺍﻡ ﺍﻟﻤﺒﻴﺽ ﺍﻟﺤﻤﻴﺩﺓ ﺃﻜﺜﺭ ﺸﻴﻭﻋﺎﹰ ﻤﻥ ﺍﻟﺨﺒﻴﺜﺔ  :ﺍﻟﺘﻀﻤﻴﻥ 
ﺜﺭ ﺍﻷﻭﺭﺍﻡ ﺍﻟﻅﻬﺎﺭﻴﺔ ﺍﻟﺴﻁﺤﻴﺔ ﺃﻜ. ﺴﻨﺔ 03-12ﻓﻲ ﻜل ﺍﻟﻔﺌﺎﺕ ﺍﻟﻌﻤﺭﻴﺔ، ﻭﺃﻏﻠﺒﻬﺎ ﺤﺩﻭﺜﺎﹰ ﻓﻲ ﻋﻤﺭ 
 
 
ﺸﻴﻭﻋﺎﹰ ﺘﻠﻴﻬﺎ ﺃﻭﺭﺍﻡ ﺍﻟﺨﻼﻴﺎ ﺍﻟﺘﻨﺎﺴﻠﻴﺔ، ﺒﻴﻨﻤﺎ ﺍﻷﻭﺭﺍﻡ ﺍﻟﻅﻬﺎﺭﻴﺔ ﺍﻟﺤﻤﻴﺩﺓ ﻭﺍﻟﺨﺒﻴﺜﺔ ﺍﻜﺜﺭ ﺇﻨﺘﺸﺎﺭﺍﹰ ﻤﻥ 
ﺍﻟﻭﺭﻡ ﺍﻟﻤﺴﺨﻲ ﺍﻟﻜﻴﺴﻲ ﺍﻟﻨﺎﻀﺞ ﺍﻜﺜﺭ ﺸﻴﻭﻋﺎﹰ ﺒﻴﻥ . ﺃﻭﺭﺍﻡ ﺍﻟﻤﺒﻴﺽ ﺍﻟﺤﻤﻴﺩﺓ، ﻭﺍﻟﺨﺒﻴﺜﺔ ﻋﻠﻰ ﺍﻟﺘﻭﺍﻟﻲ
ﺍﻟﻭﺭﻡ . ﺍﻟﻤﺼﻠﻲﺍﺃﻭﺭﺍﻡ ﺍﻟﻤﺒﻴﺽ ﺒﺼﻔﺔ ﻋﺎﻤﺔ ﻭﺃﻭﺭﺍﻡ ﺍﻟﻤﺒﻴﺽ  ﺍﻟﺤﻤﻴﺩﺓ  ﺨﺎﺼﺔ، ﻴﻠﻴﻪ ﺍﻟﻭﺭﻡ ﺍﻟﻐﺩﻱ 
ﺃﻭﺭﺍﻡ . ﺍﻟﻐﺩﻱ ﺍﻟﺴﺭﻁﺎﻨﻲ ﺍﻟﻤﺼﻠﻲ ﺍﻜﺜﺭ ﺸﻴﻭﻋﺎﹰ ﺒﻴﻥ ﺍﻷﻭﺭﺍﻡ ﺍﻟﺨﺒﻴﺜﺔ ﻭﻴﻠﻴﻪ ﻭﺭﻡ ﺍﻟﺨﻠﻴﺔ ﺍﻟﻤﺤﺒﺒﻪ
ﺃﻫﻡ ﺍﻷﻋﺭﺍﺽ ﺘﺘﻤﺜل ﻓﻲ ﺃﻟﻡ . ﻋﺎﻤﺎﹰ 04ﺍﻟﻤﺒﻴﺽ ﺍﻟﺨﺒﻴﺜﺔ ﺃﻜﺜﺭ ﺇﻨﺘﺸﺎﺭﺍﹰ ﺒﻴﻥ ﺍﻟﻔﺌﺔ ﺍﻟﻌﻤﺭﻴﺔ ﺃﻜﺜﺭ ﻤﻥ 
  .   ﺃﺴﻔل ﺍﻟﺒﻁﻥ ﻭﺘﻭﺭﻡ ﺍﻟﺒﻁﻥ
ﻋﻭﺍﻤل ﺍﻟﺨﻁﺭ ﻭﻤﻌﺭﻓﺔ ﺃﺴﺒﺎﺏ ﻤﻌﺩل ﺯﻴﺎﺩﺓ  ﻫﻨﺎﻟﻙ ﺤﻭﺠﺔ ﻟﺩﺭﺍﺴﺔ ﺸﺎﻤﻠﺔ ﻟﺘﻘﻴﻴﻡ :ﺘﻭﺼﻴﺎﺕ 
ﺇﺠﺭﺍﺀ ﺇﺨﺘﺒﺎﺭ ﺍﻟﻤﻘﻁﻊ ﺍﻟﻤﺠﻤﺩ ﻟﻠﺘﺄﻜﺩ ﻤﻥ ﻀﺭﻭﺭﺓ ﺇﺯﺍﻟﺔ ﺍﻟﻤﺒﻴﺽ . ﺍﻨﺘﺸﺎﺭ ﻫﺫﻩ ﺍﻷﻭﺭﺍﻡ ﻓﻰ ﺍﻟﺴﻭﺩﺍﻥ
ﺘﺤﺴﻴﻥ ﺇﺠﺭﺍﺀ ﺍﻟﺘﻘﺎﺭﻴﺭ ﻭﺍﻟﺘﺴﺠﻴﻼﺕ ﻟﻠﺤﺎﻻﺕ ﻭ ﺘﻔﺼﻴل ﺍﻟﺘﺸﺨﻴﺹ ﻀﺭﻭﺭﺓ ﺤﺕ ﺍﻟﺩﺭﺍﺴﺔ ﻀﻜﻤﺎ ﺃﻭ
 .  ﻭﺼﻭل ﺇﻟﻰ ﻨﺘﺎﺌﺞ ﺃﻓﻀلﺩﺭﺠﺔ ﻭﻤﺭﺤﻠﺔ ﺍﻟﻨﺴﻴﺞ ﺍﻟﻤﺭﻀﻲ ﻷﻭﺭﺍﻡ ﺍﻟﻤﺒﻴﺽ ﻤﻥ ﺃﺠل ﺍﻟﺍﻟﻭ
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1.1. INTRODUCTION 
Tumours of the ovary are common forms of neoplasms in women. (1)  
In the developed world, ovarian carcinoma are the fourth or fifth 
most common cause of death from all cancers in women, and the 
primary cause of death from gynecological malignancies; 7% of 
patients with these tumours present with advanced stage disease.(2)   
In Sudan, according to reports derived from the Department of 
Medical Statistics and Registration at RICK in the period 2009-2010, 
ovarian cancers accounted for 6.9% of all female cancers and 40.4% 
of all gynecological malignancies (including the cervix, uterus, 
vagina and vulva). No tubal malignancy was recorded in the study 
year.(3)           
The most important clinical feature in ovarian tumour is the age of 
the patient. One of eight ovarian tumours in patients less than 45 
years of age is malignant; by contrast, in older women, the 
proportion is one to three. The single most common ovarian tumour, 
the mature cystic teratoma (dermoid cyst) is encountered at all ages, 
like most tumours in the sex cord-stromal category.(4)  
Ovarian cancers account for 6% of all cancers in females.  80% are 
benign and these occur mostly in young women between ages 20 – 
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45 years. Malignant tumours are common in older women between 
the ages of 40 – 65 years. (1) 
Classification of ovarian tumours is primarily morphological. It is 
based on that the ovary containing four major types of tissue:( 5) 
1- Surface, celomic or germinal epithelium.  
2- Germ cells.  
3- Sex cord.  
4- Ovarian stroma, specialized and nonspecific.  
Surface epithelial ovarian tumours are classified accordingly to the 
following parameters:( 5) 
1- Cell type: serous, mucinous and endometrioid.  
2- Pattern of the growth: cystic, and solid.  
3- Amount of fibrous stroma.  
4- Atypia and invasiveness: benign, border line and malignant. 
Surface epithelial tumours account for two thirds of all ovarian 
neoplasms, and their malignant form about 90% of ovarian cancer in 
the Western World. (6)  
The malignant surface epithelial tumours comprise 85% of all 
ovarian neoplasms, and are the fourth most common of cancer 
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deaths in the USA. One in 70 women in industrial countries 
develops ovarian cancer and one in 100 women die of it. (7) 
A number of factors have been implicated in the causation of 
ovarian cancers. Some of the more important contributors are null 
parity, family history and hereditable mutations. (8, 9)  
The most common clinical features are increasing abdominal mass, 
pelvic pain and vaginal bleeding. 
The treatment for ovarian neoplasms depends on the grade and 
stage of the tumor at presentation. Treatment modalities include 
either cystectomy, or oophorectomy, salpingo-ophectomy, 
hysterectomy, chemotherapy and/or radiotherapy.(7)  
This study shows the patterns of ovarian neoplasms in Sudan as 
reviewed in Khartoum Teaching Hospital and the National Health 
Laboratory with regards to age, origin, risk factors, clinical 
presentation and histopathological classification.     
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1.2. LITERATURE REVIEW  
1.2.1. Normal anatomy and histology of the ovary:  
1.2.1.1. Location and description:  
Each ovary is an almond-shaped organ, measuring 4×2 cm, and is 
attached to the back of the broad ligament by the mesovarium. The 
ovary usually lies in the ovarian fossa, which is bounded by the 
external iliac vessels above and by the internal iliac vessels and 
ureter behind.  
The ovary is surrounded by a thin fibrous capsule, the tunica 
albuginea, which is covered by a layer of cuboidal cell called 
germinal epithelium. Before puberty, the ovary is smooth, but after 
puberty it becomes scarred due to successive corpora lutea 
degeneration. After the menopause the ovary becomes shrunken.(10)     
1.2.1.2. Functions:  
The ovary is responsible for the production of female germ cells, the 
ova and the female sex hormones, estrogen and progesterone, in the 
sexually mature female. These hormones have a role in the 
development of the secondary sex characteristics, ductal growth in 
the breasts, pigmentation of the areola, growth of ovarian follicles, 
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increased motility of the uterine fallopian tubes, the uterine blood 
flow and the smooth muscle of the uterus. (10, 11) 
1.2.1.3. Blood supply and lymphatic drainage:  
The ovarian arteries which supply the ovaries arise from the aorta. 
The ovarian veins drain into the inferior vena cava on the right site 
and into the left renal vein on the left. Lymphatic vessels drain into 
the paraoartic nodes. Nerve supply is derived from the aortic 
plexuses. (10)   
1.2.1.4. Histology and embryology:  
The ovary consists of a cortical region and a medullary area. The 
cortical region consists of follicles (oocytes) that are embedded in the 
stroma. The medullary region contains a rich vascular bed within a 
loose connective tissue. (12)  
1.2.1.5. Development of the ovary:  
Around the end of the first month of embryonic life, primordial 
germ cells migrate from the yolk sac to the gonadal primordial, and 
start to divide and transform into oogonia. At the first meiotic 
division, the cells are primary oocyte surrounded by follicular cells, 
many of which are lost through a degenerative process called 
atresia. Around puberty the ovaries contain 300000 oocytes. (12, 13)      
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The follicles that form during fetal life are called primordial follicles 
and consist of oocytes enveloped by a single layer of flattened 
follicular cells. The follicular growth is stimulated by follicle-
stimulating hormone, secreted by the hypophysis. The primordial 
follicle is formed by mitosis resulting in a unilaminar primary 
follicle. This follicle proliferates to form a multilaminar primary 
follicle (preantral follicle), in which follicular cells proliferate and 
form the granulosa cell layer and zona pellucida. As the follicle 
grows, the antral follicle increases in size and number of granulosa 
cells as well as fluid accumulation.  The mature Graafian follicle 
consists of theca cells which are arranged in two layers - theca 
interna and externa and granulosa cells. The theca cell interna is 
responsible for steroid production. During each menstrual cycle, 
usually one follicle grows and the other ovarian follicles undergo 
atresia. (12, 13)  
1.2.1.6. Ovulation:  
Ovulation consists of the rupture of the wall of the mature follicle, 
liberation of the oocyte, which is caught up by the dilated oviduct. 
The stimulus for ovulation is a surge of luteinizing hormone, 
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secreted by the anterior pituitary gland in response to a high level of 
circulating estrogen produced by the growing follicle.(12)  
1.2.2. Epidemiology:     
Cancer of the ovary represents about 30% of all cancers of the female 
genital organs. In developed countries, it is about as common as 
cancer of the corpus uteri (35%) and invasive cancer of the cervix 
(27%). The age-adjusted incidence rates vary from less than 2 new 
cases per 100000 women in most of South-east Asia and Africa to 
over 15 cases in Northern and Eastern Europe. But North America, 
Europe, Australia, New Zealand and temperate South America 
show higher rates. In the United State more women die from 
ovarian cancer today than from all other pelvic gynecological cancer 
sites combined.(6)  
1.2.3. Risk factors:  
There are many risk factors, some of which increase the risk of 
ovarian cancer while others reduce them.  
The factors that increased the risk:  
1- Family history: is the strongest risk factor for surface epithelial 
carcinoma. At least 10% of epithelial ovarian cancers are 
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hereditary. In USA 10 – 12% of patients have a first or second 
degree relative with ovarian cancer.(14,15,16,17,18) 
2- Mutated BRCA1 and BRCA2: About 7-10% of ovarian cancers 
are due to inherited BRCA1 or BRCA2. These mutations are 
autosomal and can be inherited from either the mother or 
father.(6)  
3- Null parity.(7)  
4- Postmenopausal women treated with a high doses of estrogen 
replacement.(6,17) 
5- Several dietary factors. (6,17) 
6- Obesity.(6,17) 
7- Endometriosis: The occurrence of ovarian cancer was 30% higher 
among women who have a history of endometriosis.(19,22)  
8- Infertility.(7,17)   
9- Smoking  is important in mucinous carcinoma.(17)      
10- Environmental agents (talc, pesticide and herbicides).(17)  
11- Alcohol consumption.(20) 
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The factors that reduced the risk:  
1- Oral contraceptive for more than 10 years.(6,17,19,21,22)  
2- Bearing children or high parity, reduces the risk factor by             
15- 20%.(6,17,21,22) 
3- Tubal ligation, reduces  the risk factor by 80%.(7,17,19,21)  
4- Breast feeding.(7,21)  
5- Hysterectomy.(17,19,22) 
1.2.4. Genetics and pathogenesis: 
1- Familial clustering: The relative risk of ovarian cancer for first 
degree relatives varies from 1.94 – 25.5, the later if both the 
mother and sister are affected.(6) 
2- BRCA 1 and 2: It is likely that  the majority of familial risk of 
ovarian cancer is explained by BRCA1 and to a lesser extend 
BRCA2.(6) 
BRCA1: is 81 Kb tumour suppressor gene located on the long arm of 
chromosome 17q21. BRCA1 protein is composed of 1863 amino 
acids. Its function is involved in transcriptional regulation, DNA 
repair, cell cycle and chromatin remodeling. Mutated BRCA1 
markedly increases the risk of developing ovarian cancer by 20-40%.   
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The histological patterns of ovarian tumours associated with BRCA1 
mutation, include epithelial tumours (carcinomas) - serous, 
mucinous, endometrioid, clear cells – as well as cancers in other 
organs including breast, colon, pancreas and prostate. (6, 23) 
BRCA2: is 84 Kb tumour suppressor gene located on the long arm of 
chromosome 13q12.3. BRCA2 protein is composed of 3418 amino 
acids. It is involved in DNA repairing through binding with BRCA1 
and RAD51 in a nuclear dot complex. Mutated BRCA2 shows a 
smaller risk for ovarian carcinoma of about 10-20% and for cancers 
in other organs such as male breast carcinoma, melanoma and 
stomach.(5)  
The other genes which contribute in ovarian carcinoma 
susceptibility include  mutated HER2- neu (ERB-B2) in about 30% of 
ovarian carcinoma,  P53 in 50% of ovarian carcinoma,  and the 
HNPCC gene (MCH1, MCH2).(6,23,24)   
1.2.5. Clinical features:  
Ovarian neoplasm causes specific and nonspecific symptoms. 
Abdominal pain or discomfort and an abdominal mass, bloating, 
loss of appetite, back pain, urinary urgency, constipation, tiredness 
and a range of other nonspecific symptoms as well as more specific 
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symptoms, such as pelvic pain, abnormal vaginal bleeding, and 
postmenopausal bleeding, involuntary weight loss, pain during sex, 
facial hair and severe acne. There can be a build up of fluid (ascites) 
in the abdominal cavity. (25, 26, 27, 28, 29)   
1.2.6. Tumour spread and staging:  
Spread occurs mainly by local extension as well as by intra-
abdominal dissemination and by lymphatic dissemination, but 
rarely by the blood stream. 
The pTNM-system is based on the postoperative pathological 
staging for histological control and confirmation of the disease.(6) 
1.2.7. Diagnosis:  
1- Start with taking history and physical examination including 
pelvic examination.  
2- Biochemical markers: Ca125 which is useful in differential 
diagnosis and in follow up of the disease, but by itself has not 
been shown to be an effective method for early stage ovarian 
cancer. Other markers include β-hCG, alpha-fetoprotein, and 
lactate dehydrogenase.  
3- Imaging including CT-scan, transvaginal ultrasound and MRI.  
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4- Cytology of aspirated fluid from the abdominal cavity to 
detect malignant cells. 
5- For a definitive diagnosis the surgical procedure is important 
to inspect the abdomen. This can be by an open procedure 
(laparotomy incision) or key surgery (laparoscopy) to enable 
suspicious areas to be biopsied and tissue sent for microscopic 
examination.(30)   
1.2.8. Treatment: 
Treatment of ovarian tumours requires a multimodality of 
cystectomy, oopherectomy, and cytoreductive surgery which 
include total abdominal hysterectomy (TAH), bilateral salpingo-
oopherectomy (BSO), omentectomy (and in a certain centers lymph 
adenoctomy), followed by adjuvant chemotherapy and 
radiotherapy.(2, 7)   
1.2.9. Prognosis:  
The most consistently reported significant prognostic indictors for 
human ovarian cancer are disease stage, tumour grade, histological 
type and the extent of surgical cytoreduction. Although these factors 
are not always related to the biological behavior or aggressiveness 
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of the disease, they are useful guidelines for selecting anticancer 
therapy. (7) The factors that influence prognosis are:( 5) 
1- Age:  younger patients have a better outcome.  
2- BRCA1 mutation and a family history.  
3- Presence and extent of tumour spread beyond ovary.  
4- Ascites is unfavorable. 
5- Border line tumour versus carcinoma: Prognosis of border line is 
good. 
6- Tumour grade and type.  
7- Psammoma bodies: Have a better prognosis.  
8- Rupture of the tumour capsule.There is no convincing  evidence 
that this complication has  any influence on survival rates 
9- DNA ploidy: Aneuploid tumours belonged to a higher grade 
and behave in a much more aggressive fashion than the diploid 
tumours.   
10- CA125: is an independent prognostic factor. 
11- P53: Over expression of P53 indicates poor prognosis.  
12- Tumour angiogenesis.  
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13- Intratumoural T-cells.The presence of tumor-infiltratingT- cells 
correlates with an improved out come in advanced ovarian 
cancer. 
14- Over expression of other markers like HER 2/neu, fatty acid 
synthase (OA. 519) and CD24.      
1.2.10. Pathology:  
1.2.10.1. Surface epithelial- stromal tumours (SESTs): 
They account for approximately 65 – 70% of all ovarian neoplasms 
and peak in the age group 20-50 years. They are sub-classified into 
benign (60%), borderline (5%), and malignant (35%).  
By definition borderline tumors lack destructive stromal invasion 
but have other histological features of malignancy (e.g. nuclear 
atypia, cellular stratification, mitotic activity). The clinical behaviour 
of these tumours is benign. The malignant surface epithelial stromal 
tumors comprise of 85-90% of all malignant neoplasms of the 
ovary.(1, 4, 6, 7)   
1- Serous tumours (STs):  
Constitute 46% of SESTs, and 20–50% of all ovarian neoplasms. They 
include three distinct entities, including serous cyst 
adenoma/adenofibroma, serous borderline tumour and serous 
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carcinoma. Grossly, the better differentiated tumour consists of 
unilocular cystic masses containing clear fluid. Many viscous 
papillary projections are often present protruding into the cavity or 
onto the surface. The malignant tumours tend to be solid and 
invasive with areas of necrosis and haemorrhage.(1, 4, 5, 6, 7)      
a. Benign serous tumours: They account for 50 -70% of STs, occur 
at any age commonly during the 5th decade. They may present 
with abdominal enlargement, pain, or vaginal bleeding. They 
are  lined by epithelium similar to that of the fallopian tube with 
ciliated and less frequently non-ciliated secretary cells.(1,4,6,7) 
b. Serous border line tumours (SBTs): They represent 5 -15% of STs 
in the age group 30-60 years. They histological criteria for their 
diagnosis are: 
 (1) Epithelial hyperplasia in form of stratification, tufting, 
cribriform, and micropapillary arrangements.  
(2) Atypia (mild to moderate).  
(3) Detached cell clusters.  
(4) Variable and usually minimum mitotic activity.  
(5) Absence of destructive stromal invasion.  
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Serous border line tumours may exhibit microinvasion. The 
behaviors of SBTs with microinvasion are similar to that of SBTs 
without microinvasion. They differ from serous carcinoma by a 
lack of destructive stromal invasion. The tumour cells are 
characterized by hyperchromatic nuclei, with variable and 
generally low mitotic activity. Up to 30% of SBTs are associated 
with tumour on the outer surface of the ovary and with 
peritoneal implants.(1,4,5,6,7)  
c. Serous adenocarcinomas: The architecture of tumours varies 
from glandular to papillary to solid. Psammoma bodies may be 
present in varying numbers. These tumours account for 25-35% 
of ST, in the age group of 40-70 years. They make up 40% of 
malignant ovarian neoplasms and 70% of ovarian surface 
epithelial stromal carcinomas. The immunoprofile is always 
positive for cytokeratin 7, epithelial membrane antigen and 
negative for cytokeratin 20, and calretinin.(1,4,6,7)   
   2- Mucinous tumours (MTs):  
Represent 36% of SESTs and 12 – 15% of all ovarian neoplasms. 
Grossly, they tend to grow larger than the serous type. They are 
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partially or completely cystic often multilocular with a fluid to 
viscous material of mucoid nature. (1, 4, 5, 6, 7) 
a. Benign mucinous tumours: consist of cystdenoma, 
cystadenofibromas and adenofibromas. They account for 80% 
of MTs and are common in the reproductive age. The glands 
are lined by mucinous columnar epithelial cells with basally 
located nuclei and no atypia. Adenofibromas are composed of 
mainly fibromatous stroma with scattered glands.(1,4,6)  
b. Mucinous borderline tumours (MBTs): constitute 10-20% of 
MT, commonly in women of 45 years. They are either 
intestinal type (85%) or endocervical type (15%). The cells 
lining the cysts are stratified (usually to no more than 3 layers) 
and form filiform intracystic papillae. Nuclei are slightly 
larger with more mitotic figures. Goblet cells and paneth cells 
are present.(1,4,5,6,7)  
c. Mucinous adenocarcinomas: They constitute less than 15% of 
MTs and less than 10% of ovarian surface epithelial stromal 
carcinomas and 10% of all malignant ovarian tumours. The 
glands are lined by malignant cells with less intervening 
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stroma. Invasion may be in  the form of infiltrative glands, 
tubules, cords or cell nests.(1,4,5,6,7)   
3- Endometriod tumours (ETs): 
They constitute about 8% of SESTs. Macroscopically they are cystic 
or solid usually with hemorrhage. (5, 7)  
a. Benign endometrioid tumours: They account for 5% of ETs. The 
histological diagnosis of endometrioid adenomas and cystic 
adenoma is based on the presence of well differentiated benign 
appearing glands or cysts lined by endometrial type of cells with 
or without squamous differentiation.(1,4,6,7) 
b. Endometrioid borderline tumours:  They comprise 20% of ETs. 
The most common is adenofibromas featuring islands of crowded 
endometrial gland or cysts lined by cells displaying grade I to 
rarely grade III cytological atypia proliferating in an 
adenofibromatous stroma. Stromal invasion is absent, mitotic 
activity is low and squamous metaplasia is common.(1,4,6,7)  
c. Endometrioid adenocarcinomas (ECs): They represent 75% of 
ETs and up to 50% of ovarian cancers. They resemble 
endometrioid carcinoma of the uterine corpus. The well 
differentiated tumour shows round, oval or tubular glands lined 
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by stratified epithelium with no mucin. Squamous differentiation 
occurs in 30–50% of cases. The cells ECs are vimetin, cytokeratin, 
epithelial membrane antigen, estrogen and progesterone receptor 
and B72.3 positive, but alpha-inhibin negative. (1,4,6,7) 
4- Clear cell tumours (CCTs):  
They represent 3% of SESTs. Macroscopically they are spongy and 
often cystic in appearance.  
a. Clear cell adenofibromas:  They constitute less than 1% of 
(CCT) and are characterized by tubular glands lined by one or 
two layers of epithelium that made up of polygonal, hobnail 
or flattened cells. The cytoplasm may be clear, slightly 
granular or eosinophilic. Nuclear atypia and mitotic activity 
are minimal.  The stroma is densely fibrous.(1,4,5,6,7) 
b. Borderline clear cell adenofibromatous tumours: They form 
less than 1% of CCTs and include those tumours in which the 
epithelium is atypical or carcinomatous without invasion.(6,7)  
c. Clear cell adenocarcinomas: Represent 99% of CCTs and 5-6% 
of all ovarian cancers. They display tubulocystic, papillary and 
solid patterns that may be pure or mixed. The tubulocystic 
pattern is characterized by variably sized tubules and cysts 
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lined by cuboidal to flatten epithelium and occasionally hob 
nailing. The immunoprolife of the cells is strongly and 
diffusely positive for keratin, epithelial membrane antigen, 
LeuM1 and B72.3 stain. (6,7) 
5- Transitional cell tumours (TCTs):  
Constitute 2% of SESTs. Macroscopically they are unilateral, firm, 
white and yellowish white. (5, 6, 7)  
a. Brenner tumours: constitute 2 -3% of all ovarian neoplasms.   
• Benign Brenner tumours: They represent 99% of TCTs and 
are characterized by nests and island of transitional type 
epithelial cells with centrally grooved “coffee bean” nuclei, 
abundant amophophilic to clear cytoplasm and distinct cell 
membrane growing in a dominant fibromatous stroma. There 
is stromal calcification. The tumor immunoprofile shows 
positivity for uroplakin, chromogranin A, serotonin, neuron 
specific endolase and is negative for cytokeratin 20. (4,6,7)   
• Border line Brenner tumours: They account for less than 1% 
of TCTs and show a greater degree of architectural complexity 
than benign ones by branching fibrovascular papillary cores 
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covered by transitional epithelium often protruding into cystic 
spaces with no stromal invasion. (4,6,7)   
• Malignant Brenner tumours: They less than 1% of TCTs. They 
are composed of crowded, irregular islands of malignant 
transitional cells with low grade features. There are stromal 
calcifications. The tumor cells are positive for uroplakin in 
some cases.(4, 6, 7) 
b. Transitional cell carcinomas: They form less than 1% of TCTs 
and are composed of papillary fronds with multilayered 
transitional epithelium and smooth luminal borders. A nested 
pattern is characterized by malignant transitional cell nests, 
irregularly distributed fibrotic stroma (malignant Brenner like 
type). Squamous differentiation occurs with no stromal 
classification. The immunoprofile shows positivity for uroplakin, 
thrombomodulin, CA125, cytokeratin 7 and negativity for 
cytokeratin 13 and 20. (5, 6, 7)     
6- Mixed epithelial tumours: 
Ovarian epithelial tumours are composed of an admixture of two or 
more of the five major cell types: serous, mucinous, endometrioid 
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and Brenner/transitional. They may be benign, border line or 
malignant. (6)  
7- Squamous cell tumour:  
a. Squamous cell carcinoma: Composed of squamous epithelial 
cells that is not of germ cell origin.  
b. Epidermoid cyst: Lined by benign keratinized squamous 
epithelium, devoid of skin appendages and unaccompanied by 
teratomatous elements are rare in ovary. (6)  
8- Undifferentiated and unclassified tumour:  
a. Undifferentiated carcinoma: Macroscopically does not have 
specific features. The tumor is predominately solid with areas of 
necrosis. Histological it consists of solid groups of tumour cells 
with numerous mitotic figures and significant cytological atypia. 
It may be accompanied with other components of mullerian 
carcinoma.(5)  
b. Unclassified adenocarcinoma: can not be classified as one of 
specific type of mullerian adenocarcinoma. (6) 
1.2.10.2. Sex cord- stromal tumours: 
These ovarian neoplasms are derived from ovarian stroma which in 
turn is derived from the sex cord of embryonic gonads. They 
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account for 5-10% of ovarian neoplasms. The malignant sex cord 
tumours constitute 2-3% of ovarian cancers. They occur at any 
age.(1,5, 6, 31) 
1- Granulosa stromal cell tumours: 
a. Granulosa cell tumours group (GCTs): They represent 1.5–3% of 
all ovarian neoplasms, 5-6% of ovarian cancers and 75% of 
estrogenic (>95% bilateral). Five percent occur prior to puberty, 
whereas 60% occur after menopause. They are encapsulated 
with a smooth, lobulated outline. They are subclassified into 
adult granulosa cell tumours and juvenile types. (1, 5, 6, 31)   
• Adult granulosa cell types: They form 95% of GCTs. There are 
composed of proliferations of granulosa cells within a stromal 
component of fibroblasts and theca luteinized cells, which have 
scanty cytoplasm and round to ovoid nuclei with a longitudinal 
groove. Mitosis rarely exceeds 1-2 per 10 high power fields. The 
tumour cells grow in a variety of patterns. The best known of 
these are the microfollicular pattern, characterized by the 
presence of Call-Exner bodies. The others include the 
macrofollicular pattern characterized by large spaces lined by 
layers of granulosa cells, insular, trabecular, diffuse 
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(sarcomatoid) and moiré silk patterns. The tumour cells are 
immunoreactive for CD99, alpha-inhibin, vimetin, cytokeratin, 
calretinin, S100 protein and smooth muscle actin and negative 
for cytokeratin and epithelial membrane antigen.(5,6,31)  
• Juvenile granulosa cell tumours: They account for 5% of 
granulosa cell tumours and are characterized by a nodular or 
diffuse cellular growth punctuated by macrofollicles of varying 
size and shape with their lumen containing eosinophilic or 
basophilic fluid. Almost all nuclei lack grooves, and mitotic 
figures are abundant.(5,6,31) 
b. Thecoma-fibroma group:   
• Thecomas: They have a distinguishable gross appearance - 
yellow in color, well defined capsule, firm consistency. They are 
about one-third as common as granulosa cell tumours and are 
characterized by cells with uniform, bland oval to spindle 
shaped nuclei with abundant, pale, vacuolated and lipid-rich 
cytoplasm. Mitosis is absent. The fibromatous component 
contains hyaline plaques and may be calcified. The tumor 
immunoprofile shows immunoactivity for vimentin and alpha-1 
inhibin.  
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• Fibromas and cellular fibromas: Grossly these tumors are 
unilateral, solid, lobulated, uniform and white. They account for 
less than 10% of ovarian neoplasms and occur at any age. 
Seventy percent of ovarian neoplasms are in this category. They 
are composed of spindle shaped cells with uniform, bland nuclei 
and scanty cytoplasm that may contain small amounts of lipid or 
occasionally eosinophilic droplets. The cells are arranged in 
fascicles or in a storiform pattern. Mitosis is absent. About 10% 
of the tumours are uniformly and densely cellular referred to as 
cellular fibroma. Fibroma cells express vimentin and may be 
immunoreactive for alpha-inhibin.(5,6)     
• Fibrosarcomas: large, solid tumours, usually unilateral, 
commonly with haemorrhage and necrosis. Histologically they 
are  densely cellular, spindle cell neoplasm with moderate to 
severe cytological atypia and a high mitotic rate (4 or more per 
10 HPF) with atypical mitotic figures.(6) 
• Stromal tumours with minor sex cord elements:  These are solid, 
histologically demonstrate the typical features of thecoma or 
fibroma in which sex cord structures are intermingled with the 
fibrothecomatous cells.(6 )  
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• Sclerosing stromal tumours: Unilateral and sharply demarcated. 
There is pseudo-lobulation of cellular area separated by 
hypocellular areas of densely collagenous tissue. They are 
immunoreactive for desmin, SMA and vimentin.  
• Signet-ring stromal tumours: Macroscopically solid and cystic, 
these tumors show diffuse proliferation of spindle cells. The cells 
show eccentric nuclei with single large cytoplasmic vacuoles. 
They are negative for mucin which distinguishes them from 
Krukenberg tumours.(6) 
2- Sertoli-stromal cell tumours: 
• Sertoli-Leydig cell tumours (SLCTs) group: Are uncommon, less 
than 1% of ovarian neoplasms. Macroscopically they are 
unilateral, solid, cystic, fleshy and pale yellow. Areas of necrosis 
or haemorrhage are frequent. In well differentiated SLCTs,  
Sertoli cells are present in opened or closed tubules and lack 
significant nuclear atypia or mitotic activity within a fibrous 
stroma. In intermediate tumors lobules are composed of 
hyperchromatic spindle-shaped cells. In poorly differentiated 
tumors a sarcomatoid stroma resembling primitive gonadal 
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stroma is the dominant feature. They are immunoreactive for 
vimentin, keratin and alpha-inhibin.(6,31)   
• Sertoli-Leydig tumours with heterologous elements: Occur in 5% 
of SLCTs and usually consist of cartilage, skeletal muscle or 
rhabdomyosarcoma. They may be admixed with sex cord areas of 
tumour. They are immunoreactive for cytokeratin 7, epithelial 
membrane antigen (EMA), vimentin, and alpha-inhibin. (6)     
• Retiform Sertoli-Leydig cell tumours and variant with retiform 
elements: Contain papillae comprising a complex microcystic 
pattern. The lining cells may be flattened with eosinophilic 
material in the lumen. They are  immunoreactive for cytokeratin 
and alpha-inhibin.(6) 
• Sertoli-cell tumours: They are made up of tubules which are 
either open or closed, simple or complex. Simple tubules are 
surrounded by a basement membrane and contain a central 
hyaline body. The complex tubule form has multiple lumens 
filled with hyaline bodies surrounded by a thick basement 
membrane. The immunoprofile of tumor cells show positivity for 
keratin, vimentin and alpha-inhibin. Electron microscopy 
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diagnostic feature is the presence of Charcot Bottcher filament 
and Spangaro bodies.(6) 
• Stromal-leydig cell tumours:  Are rare, well circumscribed and 
have two components spindle-shaped or ovoid stromal cells 
identical to those of fibroma or thecoma are present together with 
Leydig cells containing Reinke crystals.(6)   
3- Sex cord-stromal tumours of mixed or unclassified cell types: 
These tumors do not satisfy granulosa stromal, sertoli-stromal or 
steroid cell categories.  
• Sex cord-stromal tumours with annular tubules: Show Sertoli cells 
with pale cytoplasm and nuclei arranged antipodally around a 
single hyaline body or multiple hyaline bodies.  
• Gynandroblastoma: Well formed hallow tubules lined by Sertoli 
cells that are generally admixed with rounded islands of granulosa 
cells growing in a microfollicular pattern.   
• Unclassified sex cord-stromal tumours: The cells show a pattern 
intermediate between granulosa stromal cell tumour and Sertoli-
stromal cell tumours.(6)    
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4- Steroid cell tumours:  
Are composed of cells that resemble steroid hormone-secreting cells. 
These include stromal luteoma, steroid cell tumours, not further 
classified and the Leydig cell tumours.  
• Sertoli cell tumours not otherwise specified: Large, well 
circumscribed having lobulated appearance, composed of solid 
aggregate of cells with occasional nests or trabeculae. The tumour 
cells are polygonal with cytoplasm that is granular and esinophilic. 
The cells show nuclear atypia and mitosis. They are positive for 
alpha-inhibin.  
• Stromal luteoma: Are composed of nodules of luteinized stromal 
cells that are arranged diffusely, in nest or cords. The cytoplasm is 
pale with eosinophilic bland nuclei and mitosis is rare. 
• Leydig cell tumours:  A rare ovarian steroid neoplasms composed 
of Leydig cells that contain crystals of Reinke and is associated 
with androgen manifestations. It is positive for alpha-inhibin and 
vimentin. 
• Hilus cell tumours: Brown to yellow on gross appearance, well 
circumscribed lesion, composed of cells with abundant cytoplasm 
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that is usually eosinophilic, but may be clear with intracytoplasmic 
lipid and characteristic Reinke crystals may be present.  
•  Leydig cell tumours non hilar type: Macroscopically well 
circumscribed lesion and centered in the medullary region. 
Histologically these tumors are  composed of steroid cells without 
discernible lipid and surrounded by ovarian stroma that shows 
stromal hyperthecosis with Reinke crystals.(6)  
1.2.9.3. Germ cell tumours:  
Constitute 15-30% of primary ovarian tumours with mature cystic 
teratomas (dermoid), benign, being the most common subtype 
(95%). They are mostly seen in children and young adults.  
Malignant primitive germ cells represent 3-5% of all ovarian 
malignancy.(1,5,6,31)   
1- Primitive germ cell tumours:  
• Dysgerminomas: They account for 50% of all malignant germ cell 
tumours, less than 1% of all ovarian neoplasms and 1-5% of all 
malignant ovarian tumours. They occur at any age with the vast 
majority occurring in the second and third decades. Encapsulated 
tumours, unilateral, solid, uniform, and white. Histologically, 
germ cells have a monotonous appearance with a polygonal 
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shaped, abundant pale cytoplasm, uniform nuclei and a variable 
amount of chronic inflammatory cells composed of T 
lymphocytes. The immunoprolife of the tumour cells shows 
positivity for vimentin, and placental-like alkaline 
phosphatase.(1,5,6,31)    
• Yolk sac tumours: Represent 20% of all malignant germ cell 
tumours. Encapsulated, soft and grey-yellow tumour, with 
necrosis and haemorrhage. Histologically, the characteristic 
reticular patterns formed  by a loose, basophilic, myxoid stroma 
harbouring a mesh work of microcytic space lined by clear or 
flattened epithelial cells with various degrees of atypia and 
cytoplasmic PAS positive, diastase-resistant hyaline globules. 
There are several histological variants - polyvesicular vitelline, 
solid yolk sac tumour, parietal yolk sac tumour, glandular types 
of yolk sac and hepatoid yolk sac tumour. The cells are positive 
for AFP.(5,6,31) 
• Embryonal carcinomas and polyembryomas: Histologically, 
embryonal carcinomas reveal disorganized sheets of large 
primitive AFP and CD 30 positive cells forming papillae. 
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• Non gestational choriocarcinomas:  A rare germ cell tumour 
composed of cytotrophoblast, syncytiotrophoblast and 
extravillous trophoblast. Morphologically it is identical to 
gestational choriocarcinoma with hormonal manifestation such 
as precocious pseudopuberty.(6) 
• Mixed germ cell tumours: Are composed of at least two different 
germ cell elements of which at least one is primitive. The majority 
are a combination of dysgerminoma and yolk sac. Others include 
immature or mature teratoma, embryonal carcinoma and 
choriocarcinoma. They are malignant.(6)  
2- Biphasic or triphasic teratomas:   
Are composed of two of three primary germ layers (ectoderm, 
mesoderm and endoderm).  
• Immature teratomas: Represent 3-4% of all ovarian teratoma,       
15-20% of all primitive germ cell tumours and 1% of all ovarian 
cancers. They contain immature embryonal tissue types and occurr 
during the first two decades of life. Macroscopically these tumours 
are usually unilateral variegated, solid and fleshy. Histologically  
they are composed of neuroectodermal rosettes and tubules 
admixed with mature tissues.(5,6,31)       
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• Mature teratomas: Comprise 96% of all germ cell tumours and  
20–44% of all ovarian neoplasms. They occur during the 
productive years. Macroscopically, cystic or solid lesion, 
containing sebaceous material, hair, teeth, and bone. 
Histologically they are composed of adult type tissue derived 
from two or three embryonic layer. Benign tumours such as 
stroma ovarii, corticotroph cell adenoma, prolactinomas, naevus, 
and glomus tumour may arise within atypical dermoid cyst.(5,6,31)     
3- Monodermal teratoma and somatic-type tumour associated with 
dermoid cyst:   
• Stroma ovarii:  It accounts for 2-7% of all ovarian teratomas, 
0.01% of ovarian neoplasms, with age presentation in the 5th 
decade. This tumor is identical to thyroid adenoma or carcinoma. 
Macroscopically, unilateral brown, solid and gelatinous lesion. 
Histologically, it is composed of normal or hyperplastic thyroid-
type tissue with microfollicular, macrofollicular, trabecular and 
solid patterns. It is immunoreactive for thyroglobulin.(5,6,31)    
•  Carcinoid: It represents less than 1% of ovarian teratomas, 
presents in the age range 14-79 years. It may be cystic or solid, 
composed of round cells with uniform nuclei and abundant 
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eosinophilic cytoplasm, enclosing small red argentaffin granules 
at the peripheral of the nest. There are trabecular, mucinous or 
stromal Carcinoid patterns.  The immunoprofile of the tumour 
cells shows positivity for chromogranin and synaptophycin.(5,6,31) 
• Neuroectodermal tumour: Morphologically identical to their 
nervous system counterparts. They are divided into three 
categories, well differentiated form such as ependymoma, poorly 
differentiated, such as primitive neuroectodermal tumour 
(PNET) and medulloepithelioma and anaplastic form such as 
glioblastoma multiforme. They are immunoreactive for glial 
fibrillary acidic protein, vimentin, CD99, cytokeratin, desmin and 
chromogranin.  
• Retinal anlage tumour group: Macroscopically, pigmented areas 
that correspond to solid nests, tubules and papillae composed of 
atypical cells with melanin-containing cytoplasm.  
• Carcinomas: Dermoid cysts in which a secondary carcinoma 
develops include squamous cell carcinoma, accounting for 80% of 
cases, adenocarcinoma and basal cell carcinoma.  
• Melanocytic tumour: Rare, occurring much less commonly than 
metastatic melanoma.  
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• Sebaceous tumour: Arise from an ovarian dermoid cyst. 
Histologically it is composed of large number of mature foamy or 
buffly sebaceous cells with positivity for oil red O.         
• Sarcomas: Account for 8% of cases of malignancy in dermoid cyst 
and seen in younger.  
• Pituitary-type tumour: Composed of corticotroph cell adenoma 
and prolactinoma that are responsible for Cushing’s syndrome 
and hyperprolactinaemia respectively.(6)   
4- Germ cell sex cord-stromal tumour:   
•  Gonadoblastoma: Composed of tumour cells resembling 
dysgerminoma or seminoma, admixed with sex cord derivated 
cells resembling immature Sertoli or granulosa cells. 
• Mixed germ cell-sex cord-stromal tumour: Composed of germ 
cells and sex cord derivative, resembling immature Sertoli or 
granulosa cell. They have cord-like or trabecular, tubular 
haphazard and mixed patterns.(6)  
1.2.9.4. Tumours and related lesions of the rete ovarii:   
A varied group of benign and malignant tumours and related 
lesions that originate from the rete ovarii, a vestigial structure 
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present in the ovarian hilus, composed of cuboidal or columnar non-
ciliated cells arranged in retiform spaces. 
• Adenoma: Occur as an incidental finding in middle aged women. 
They are composed of closely packed elongated tubules. 
• Cystadenoma and cyst adenofibroma: They are tubulopapillary 
cystic proliferation of clear columnar cells. Stroma is densly 
populated by luteinized cells and cause irregular bleeding in 
postmenopausal patients.  
• Adenomatous hyperplasia: Similar to the same lesion in the testis. 
It is differentiated from adenoma only by its poorly defined 
margin.  
• Cyst: Unilocular, their linings consist of cuboidal-columnar non-
cilicated cells. The walls contain tracts of smooth muscle and foci 
of hilus cells.(6)  
1.2.9.5. Miscellaneous tumours and tumour-like condition of the 
ovary:   
• Small cell carcinoma, hypercalcaemic type: Occur in young, and 
is associated with paraendocrine hypercalcaemia in two thirds of 
patients. Macroscopically, large, solid, with necrosis and 
haemorrhage. They form follicle-like spaces that contain 
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eosinophilic fluid and the nuclei show nucleoli. They are positive 
for epithelial membrane antigen. 
• Small cell carcinoma, pulmonary type: Large, solid, with cystic 
components. Histologically resemble small cell carcinoma of the 
lung and is associated with surface epithelial stromal tumors. The 
neoplastic cells have nuclei with finally stippled chromatin, lack 
nucleoli and show molding. The cytoplasm is scanty with 
numerous mitoses.   
• Large cell neuroendocrine carcinoma: Consists of medium to 
large cells, nuclei with prominent nucleoli and frequent mitoses. 
They are immunoreactive for chromogranin.        
• Hepatoid carcinoma:  resembles hepatocellular carcinoma. The 
tumour cells are arranged in sheets, cords and trabeculae with          
a moderate to abundant amount of eosinophilic cytoplasm and 
distinctive cell border and frequent mitoses. PAS-positive 
diastase-resistant hyaline globules and Hall stain-positive bile 
pigment can be seen. 
• Tumours resembling adenoid cystic carcinoma and basal cell 
tumour: Resemble adenoid cystic carcinoma and basal cell 
tumour of salivary gland or cutaneous basal cell carcinoma but 
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lack the myoepithelial cell component. The cribriform pattern is 
composed of uniform small cells surrounding round lumens and 
the cysts are typical in the case of basal cell tumour pattern 
consisting of aggregates of basaloid cells with peripheral 
palisading. They are immunoractive for S-100 and actin.  
• Ovarian malignant mesothelioma:  No history of asbestos 
exposure, involves both serosa and the parenchyma of the ovary. 
Histologically they are analogous to peritoneal mesothelioma.  
• Gestational choriocarcinoma: Consists typically of a 
haemorrhagic mass. It is a rare tumour composed of both 
cytotrophoblast and syncytiotrophoblast cells that arise as a 
result of an ectopic ovarian pregnancy.  
• Hydatidiform mole: is an ectopic ovarian molar pregnancy. It has 
hydropic chorionic villi with cistern formation and trophoblast 
proliferation.  
• Ovarian wolffian tumour: It is more common in the broad 
ligament but can also occur in the ovary. The tumour epithelium 
shows a diffuse, tubular or hallow tubular pattern. The cells are 
positive for cytokeratin 7 and 19 as well as vimentin.  
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• Wilms tumour: Primary ovarian neoplasm that has the typical 
feature of Wilms tumour of the kidney - composed of small 
tubules, glomeruloid structures and blastema.  
• Paraganglioma: is a neuroendocrine neoplasm, consists of 
polygonal epithelioid cells arranged in nests separated by a 
fibrovascular stroma. It is positive for chromogranin.  
• Myxoma: sharply demarcated, large, soft with cystic 
degeneration, consists of spindle and stellate-shaped cells within 
abundant well vascularized myxoid background, positive for 
vimentin and smooth muscle actin. Ultrastructural feature of thin 
filament condensed into dense bodies also support the presence 
of myofibroblast.(6)  
• Malignant soft tissue tumours not specific to the ovary: Pure soft 
tissue sarcoma of somatic type occurs as primary tumour of the 
ovary.  Includes fibrosarcoma, leiomyosarcoma, malignant 
peripheral nerve sheath tumor, angiosarcoma, 
rhabdomyosarcoma, osteosarcoma and chondrosarcoma. 
•  Benign soft tissue tumours not specific to the ovary: Of the 
remaining soft tissue tumour, leiomyoma, haemangioma, neural 
tumour, lipoma, lymphangioma, chondroma and osteoma.(6) 
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1.2.9.6. Tumour-like condition of the ovary:   
• Luteoma of pregnancy: Found incidentally at term during 
caesarean section. Histologically, there is diffuse proliferation of 
polygonal eosinophilic cells that contains little or no lipid. The 
nuclei are round and contain prominent nucleoli, positive for 
alpha-inhibin, CD99, cytokeratin and vimetin.    
•  Uncommon tumour-like condition associated with pregnancy: 
Include hyperreactioluteinalis, large solitary luteinized follicle cyst 
of pregnancy and pureperium.  
•  Stromal hyperthecosis: There is hyperplastic stroma which 
contains clusters of luteinized stromal cell. 
• Stromal hyperplasia: Diffuse densely cellular proliferation of 
small stromal cells with scanty amount of collagen.  
• Fibromatosis: Proliferation of spindle-shaped fibroblasts with a 
variable, but usually large amount of collagen.  
• Massive ovarian oedema: Edematous, hypocellular, ovarian 
stroma with preserved architecture.  
•  Other tumour-like conditions: Mimic an ovarian neoplasm; 
include follicle cyst, corpus luteum cyst, polycystic ovarian 
disease and endometriosis.(6)  
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1.2.9.7. Lymphomas and leukemia:   
• Malignant lymphomas: Occurs in the fourth and fifth decades. 
Burkitt’s lymphoma may account for about one half of cases of 
malignant ovarian neoplasm. It is bilateral, white in colour with 
foci of haemorrhage or necrosis. The tumour cells proliferate in 
cords, islands and trabeculae with occasional follicle-like spaces. 
The most common are diffuse large B cell, Burkitt’s and follicular 
lymphoma.  
• Leukaemia: May be primary or secondary, the latter is more 
common. Primary granulocytic sarcoma of the female genital 
tract including 7 cases of the ovary was reported. The ovarian 
tumors are usually large and may be unilateral or bilateral, solid, 
soft and white, called chloroma. Histologically granulocytic 
sarcomas have a predominantly diffuse growth with a cord-like 
pattern. The nuclei show fine dispersed chromatin with abundant 
cytoplasm.  
•  Plasmacytoma: Identical to plasma cell myeloma. The tumour 
cells may be mature or immature. The mature type has eccentric 
nuclei with clumped chromatin, low nuclear to cytoplasm ratio, 
abundant cytoplasm and prominent perinuclear halos. The 
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immature forms are pleomorphic with frequent multinucleated  
cells.(6)     
1.2.9.8. Secondary tumours of the ovary: 
Malignant tumours metastasize to the ovary from extraovarian 
primary neoplasms.  
General features of ovarian metastasis include bilaterality, small 
multinodular surface, extensive extraovarian spread, unusual 
histological feature, blood vessels and lymphatic invasion and 
desmoplastic reaction. They account for 5-8% of ovarian cancers. 
The routes of tumour spread to the ovary are variable. Lymphatic 
and haematogenous metastasis to the ovary is the most common 
form of dissemination. Direct extension is common. The most 
common tumours are colonic adenocarcinoma, pancreas, gastric, 
biliary tract, and appendix and breast carcinoma.  
Krukenberg tumour is almost always secondary to gastric 
carcinoma, but may occasionally originate in the intestine, appendix 
or breast. (6)    
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1.3. OBJECTIVES 
 
1.3.1. General objectives:  
To study the patterns of ovarian neoplasms among Sudanese 
females diagnosed at the National Health Laboratory and Khartoum 
Teaching Hospital from January 2009 through to January 2010 to 
determine the clinicopathological features of these neoplasms.  
 
 
1.3.2. Specific objectives:  
• To determine the histopathological patterns of ovarian neoplasms 
among Sudanese females.  
• To determine the age, residence distribution, and clinical 
presentation of ovarian neoplasms in the studied group. 
• To determine the common diagnostic procedures used in the 
diagnosis of ovarian neoplasms among Sudanese females. 
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2. MATERIALS AND METHODS  
2.1. Study design:  
This is a descriptive, retrospective, recorded data-based study. 
2.2. Study duration:  
The study was carried out from January 2009 through to January 
2010.   
2.3. Study area:   
The study was conducted at the National Health Laboratory (NHL) 
and Khartoum Teaching Hospital (KTH), Sudan. 
The NHL stands as a National Reference Laboratory, located at 
center of Khartoum. It receives samples from different parts of 
Sudan. It has several departments including a histopathology 
department. It contains the Cancer Research Center of Sudan.  
KTH is located at the center of Khartoum. It is one of the major 
hospitals in Sudan providing nation wide diagnostics, management, 
training and research services.       
2.4. Study population:  
All cases of ovarian neoplasms presented to NHL, KTH during the 
period of the study.  
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2.4.1. Inclusion criteria:  
Patients of ON who were diagnosed histopathologically at the two 
above mentioned centers.  
Additional information was obtained by telephone from the patients 
to complete the request forms. 
2.4.2. Exclusion criteria:  
Patients with ovarian neoplasms who had no histopathological 
slides in the histopathology departments at NHL and KTH.  
2.5. Sampling technique:                                        
2.5.1. Ethical consideration:  
Consent was obtained from the Director General of National Health 
Laboratory and of Khartoum Teaching Hospital.   
2.6. Data collection:   
Data was collected from the patients’ request forms in a pre-
designed questionnaire with detailed history and investigations. 
The histopathological slides of patients included in the study were 
retrieved and reviewed by me and experienced histopathologist to 
confirm ovarian neoplasm diagnosis, determine the 
histopathological type of the tumour, and classify the ON using the 
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WHO classification. Microscopic pictures were obtained using 
Olympus BX51 and DP70 video microscopy system at NHL.  
2.7. Data Analysis:  
The data collected was analyzed statistically by computer using 
Statistical Package for Social Sciences (SPSS). Hypnosis testing was 
carried out using Pearson's chi-squared test for proportions at a 
significance level at P= .05. 
Results obtained from data analyses, were presented in tables and 
charts by Microsoft words and Excel Program.  
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RESULTS 
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Fig. 1: Distribution of ovarian neoplasms according to age (n = 141)  
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Fig. 2: Distribution of ovarian neoplasms according to residence in 
different regions in Sudan (n = 80)  
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Fig. 3: Distribution of ovarian neoplasms according to marital status 
 (n = 90)  
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Fig. 4: Distribution of ovarian neoplasms according to parity (n = 70)  
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Fig. 5: Distribution of ovarian neoplasms according to family history  
(n = 67)  
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Table 1: Distribution of presenting complaints among studied 
patients of ovarian neoplasms   
Clinical remarks Frequency  Percentage  
Lower abdominal pain 73 51% 
Abdominal mass 38 26.60% 
Irregular cycle 12 8.40% 
Vaginal bleeding 7 4.90% 
Postmenopausal bleeding 8 5.60% 
Ascites  2 1.4% 
Others 14 9.8% 
 
 
 
Table 2: Distribution of ovarian neoplasms according to duration 
of the symptoms (n = 41) 
Duration (months) Frequency Percentage 
< 6  27 65.9% 
> 6 14 34.1% 
Total  41 100.0% 
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Table 3: Distribution of ovarian neoplasms according to 
modalities of diagnosis (n = 95) 
Modality of diagnosis Frequency Percentage 
U/S 78 82.10% 
U/S + CT scan 8 8.42% 
CT scan 4 4.21% 
During cesarean section 3 3.15% 
MRI 1 1.1% 
U/S+MRI 1 1.1% 
Total  95 100.0% 
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Fig. 6: Type of specimens among the studied group (n=143)    
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Fig. 7: Distribution of behaviour patterns of histological type of ovarian 
neoplasms (n = 143)  
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Table 4: Relation between behaviour patterns of histological  
type of ovarian neoplasms and the age (n = 141) 
Age (in years) 
Histological type Total 
Benign Malignant 
0-10 0 (0.00%) 1 (3.2%) 1 (0.70%) 
11-20 4 (3.6%) 1 (3.2%) 5 (3.5%) 
21-30 42 (38.2%) 6 (19.4%) 48 (34.0%) 
31-40 22 (20.0%) 7 (22.6%) 29 (20.6%) 
41-50 22 (20.0%) 8 (25.8%) 30 (21.3%) 
51-60 9 (8.2%) 2 (6.5%) 11 (7.8%) 
61-70 8 (7.3%) 3 (9.7%) 11 (7.8%) 
71-80 3 (2.7%) 3 (9.7%)  6 (4.3%) 
Total  110 (100.0%)  31 (100.0%)  141 (100.0%) 
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Table 5: Histological type of ovarian neoplasms among the 
studied patients (n = 143) 
 
Type  Frequency Percentage Percentage 
From total  
Surface epithelial stromal tumour 
• Serous tumour:  
- Benign  
- Malignant  
- Borderline  
• Muscinous tumour:  
- Benign  
- Borderline 
• Endometrioid tumour:  
- Malignant  
• Transitional  tumour:  
- Brenner tumour 
? Benign  
? Malignant  
75 
58 
44 
8 
6 
12 
11 
1 
3 
3 
2 
2 
1 
1 
52.4% 
77.3% 
75.9% 
13.8% 
10.3% 
16.0% 
91.7% 
8.3% 
4.0% 
100.0% 
2.7% 
100.0% 
50.0% 
50.0% 
 
40.6% 
30.8% 
5.6% 
4.2% 
8.4% 
7.7% 
0.7% 
2.1% 
2.1% 
1.4% 
1.4% 
0.7% 
0.7% 
Germ cell tumour 
• Teratoma:  
- Mature cystic   
- Monodermal  
? Stroma ovarii 
? Carcinoid 
- Immature   
• Dysgerminoma 
52 
50 
46 
3 
2 
1 
1 
2 
36.4% 
96.2% 
92.0% 
6.0% 
67.0% 
33.0% 
2.0% 
3.8% 
 
35.0% 
32.2% 
2.1% 
1.4% 
0.7% 
0.7% 
1.4% 
Sex cord stromal tumour 
• Granulosa stromal cell type:  
    - Granulosa cell tumour 
? Adult type   
? Juvenile type 
- Thecoma 
- Fibroma 
14 
14 
7 
6 
1 
4 
3 
9.8% 
100% 
50.0% 
85.7% 
14.3% 
28.6% 
21.4% 
 
9.8% 
4.9% 
4.2% 
0.7% 
2.8% 
2.1% 
Lymphoid tumour 
Metastatic malignancy 
1 
1 
0.7% 
0.7% 
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Table 6: Relation between behaviour patterns of ovarian tumours 
and classification of ovarian neoplasms (n = 143) 
Classes of tumours 
Type 
Total  Benign 
% of all 
Benign Malignant 
% of all 
Malignant  
Surface epithelial tumour  56 (74.7%) 50.5% 19 (25.3%) 59.4% 75  (100.10%) 
Germ cell tumour 48 (92.3%) 43.2% 4 (7.7%) 12.5% 52 (100.0%) 
Sex cord-stromal tumour 7 (50.0%) 6.3% 7 (50.0%) 21.9% 14  (100.0%) 
Lymphoid tumour  0 (0.0%) 0% 1 (100.0%) 3.1% 1 (100.0%) 
Metastatic tumour 0 (0.0%) 0% 1 (100.0%) 3.1% 1 (100.0%) 
Total  111    100.0% 32    100.0% 143   
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Table 7: Distribution of benign ovarian neoplasms among  
Studied patients (n = 111) 
Diagnosis  Frequency Percentage 
Mature cystic teratoma  46 41.4% 
Serous cyst adenoma  44 39.7% 
Mucinous cyst adenoma  11 9.9% 
Thecoma tumour 4 3.6% 
Fibroma tumour 3 2.7% 
Stroma ovarii tumour 2 1.8% 
Brenner tumour  1 0.9% 
Total  111 100.0% 
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Table 8: Distribution of malignant ovarian neoplasms among 
studied patients (n = 32) 
Diagnosis  Frequency Percentage 
Serous cyst adenocarcinoma 8 25% 
Granulosa cell tumour 7 21.9% 
Serous borderline tumour 6 18.8% 
Endometroid carcinoma  3 9.4% 
Dysgerminoma tumour 2 6.3% 
Mucinous borderline tumour 1 3.1% 
Brenner tumour  1 3.1% 
Carcinoid tumour 1 3.1% 
Immature teratoma tumour 1 3.1% 
Lymphoid tumour  1 3.1% 
Metastatic adeno/Krukenberg  1 3.1% 
Total  32 100.0% 
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Figure 8:  Photomicrograph of Burkitt’s lymphoma shows starry sky 
appearance, tingible body macrophages and tumour cells molding 
H/E, X40 
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Figure 9: Photomicrograph of carcinoid tumour shows trabecular 
patterns with pepper –salt appearance of nuclei H/E, X40  
 
Figure10:  Photomicrograph of carcinoid tumour shows cytoplasmic 
staining evidenced by neuron specific endolase X40 
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Figure 11: Photomicrograph of malignant Brenner tumour demonstrates 
nuclear atypia and mitotic figure H/E, X40  
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Figure 12: Photomicrograph of dysgerminoma tumour shows uniform 
cells with one or more prominent nucleoli and numerous inflammatory 
cells H/E, X40  
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Figure 13: Photomicrograph of immature teratoma demonstrates 
primitive neuroepithelial elements H/E, X10  
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Figure 14: Photomicrograph of stroma ovarii tumour shows thyroid 
follicles and colloid H/E, X40  
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Figure 15: Photomicrograph of mature cystic teratoma shows 
keratinized squamous epithelium and sebaceous glands H/E, X10  
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Figure 16: Photomicrograph of metastatic adenocarcinoma demonstrates 
malignant glands and single cells in pool of mucin H/E, X10 
 
 
Figure 17:   Photomicrograph of metastatic adenocarcinoma shows 
presence of intra and extracellular mucin evidenced by PAS stain X40 
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Figure 18:  Photomicrograph of serous cyst adenocarcinoma shows 
pleomorphic vesicular nuclei and mitotic figure H/E, X40  
 
 
 
 
 
 
 
 
 70
 
 
 
 
 
Figure 19: Photomicrograph of granulosa cell tumour demonstrates 
Call-Exner bodies H/E, X40  
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DISCUSSION 
This is a descriptive retrospective study of ovarian neoplasms in 
Sudanese females. It was carried out in the period from January 
2009 to January 2010. The total number of patients with ovarian 
neoplasms diagnosed at NHL and KTH during the study was 150 
cases. Of these 7 had missed slides and consequently were excluded 
from the study. One hundered and forty three cases were analyzed.  
Ovarian neoplasms are a heterogenous group of tumours with 
different subtypes and different behavioral processes. This had led 
various authors to study different and specific entities within the 
same topic. 
This study encountered many difficulties and limitations due to the 
quality of the registered data on which the study was based, in 
particular the poor clinical history details and information. So 
caution has to be taken in the interpretation of the results and their 
comparison with the international data. 
In this study, the age of 141 studied patients ranged from 9-80 years 
of age, with a mean of 39.96 ± 16.18 years. The youngest patient was 
9 years old. The commonest age group was 21–30 years (n=48) 
34.0%as shown in (Figure 1). A study carried by Jha et al., in Nepal 
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in 161 patients (2004-2008) showed the most common age group 
was 21-40 years 47.2%(32), so the ovarian neoplasms occurred 
mainly in reproductive period.  
Geographically, most of patients (n=27) 33.8% originated from 
western and the second most common from northern Sudan 
(n=23)28.8% as shown in (Figure 2). 
As regard to marital status in this study married women 
represented (n=74)82.2% while single women (n=16) 17.8% as 
shown in (Figure 3). 
We found in this study that women who have three or less children 
had an increase risk factor of ovarian tumours (n=37)52.9% as 
shown in (Figure 4). 
The presence of a family history of ovarian cancer and breast cancer 
is a strong risk factor for ovarian cancers. In our study family 
history (n=8)11.9% was not found to be a risk factor and it may be 
due to the small size (Figure 5). In a study carried out by Wasim, et 
al in Pakistan in 110 patients cancers in (2005 – 2007), 3.6% had a 
family history of ovarian. (33) 
The commonest presenting symptom was lower abdominal pain 
and it occurred in (n= 73)51% of our patients. Then, abdominal 
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mass represented (n=38) 26.6% (Table 1). These results were similar 
to those in Elobied’s(34) study, which was performed on 125 cases of 
ovarian lesions in which 55 cases had ovarian neoplasms at Soba 
University Hospital and  NHL,  and in Wasim’s, et al.,(33) study. But 
different to Yasmin’s, et al (35) study which was carried in Pakistan 
in 63 patients and showed 70.6% of cases had lower abdominal pain 
while 14.71% had an abdominal mass.     
In this study (n=27) 65.9% of patients had symptoms for less than 6 
months, while (n=14) 34.1% had symptoms for more than 6 months 
(Table 2). The exact time lapse between the beginning of symptoms 
and diagnosis of ovarian neoplasm is variable. In our study it varies 
from 3 day to 3 years. 
In this study the percentage of cases of ovarian neoplasms 
diagnosed first by ultrasonography was high(n=78) 82%, compared 
to (n=1) 1.1% by MRI, and (n=1)1.1% by MR1 + U/S (Table 3). In 
comparison a prospective study of 1066 women carried out by 
Timmerman et al.(36), showed that experienced ultrasound 
examiners correctly classified 93% of the tumours as benign or 
malignant. Ultrasonography is a non-invasive radiological 
procedure which is easy and available. This is probably requested 
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first, suggesting a diagnosis of ovarian tumour.  However the 
definite diagnosis is by biopsy. 
Concerning the type of specimens, most of the type of specimens 
was oophorectomy (n=77) 53.8%, compared to (n=7)4.9% incisional 
biopsy (Figure 6). So it is preferable to do frozen sections first 
instead of removing the ovary, so as to avoid unnecessary removal 
of the ovary.  
In this study benign ovarian tumours represented (n=111) 77.6% 
and malignant ones represented (n=32) 22.4% (Figure 7). These 
findings are similar to Wasim’s et al. (33) study which showed that 
72% of ovarian tumours were benign and 28.0% were malignant. In 
a study done by Jha et al.,(32) benign ovarian tumours were 83.9% 
and malignant ones were 16.1%, however, these figures were only 
89.7% of benign ovarian tumours  and 10.3% of malignant ones in a 
study carried out by Yasmin,  et al.,  respectively.(35)  
For all age groups, benign tumours were more common than 
malignant ones. In our study most benign ovarian tumours (n=42) 
38.2% occurred in the age group 21-30 years old, whereas most of 
malignant tumours (n=16) 51.6% occurred in patients above 40 
years of age (P value 0.325), (table 4). These results are comparable 
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to Jha’s study which showed 51.9% of benign ovarian tumours in 
the age group 21-40 years and malignant tumours were 73.1% in 
the ages above 40.(32) However the latter figure was 76.1%  of 
malignant tumours above age of 40 years in a study carried by 
Dhakal, et al., in 97 patients in Nepal (1999-2004).(37)   
Most ovarian tumours in this study were surface epithelial- stromal 
tumours (n=75) 52.4% as shown in (Table 5). These results were 
similar to Jha’s study,(32) 52.2% and Elobied’s(34) study 47.3%, 
however, this figure was only 76.5% in Yasmin’s study.(35) Benign 
surface epithelial tumours comprised (n=56 ) 50.5% of all benign 
ovarian tumours, whereas their malignant counterpart formed 
(n=19)59.4% of all malignant ones (Tables 5, 6). These results 
compared to Jha’s study 48.9%, 69.2% respectively and Elobied’s 
study 38.2% & 61.9% respectively.(32,34) Benign surface epithelial 
tumours constituted (n=56) 39.1% of all ovarian tumours, (n=56) 
74.7% of surface epithelial tumours. Of the patients with benign 
surface epithelial tumours (n=44)78.6% had serous, (n=11) 19.6% 
had mucinous and (n=1) 1.7% had Brenner tumours (Table 5, 6). A 
retrospective study carried out by Tuncer, et al.,(38) in Turkey 
(212/2216) patients showed these figures 9.2%, 28.5%, 49.0%, 4.3% 
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6.7% respectively. Another study carried out by Elobied showed 
23.6%, 47.3%, 84.6% and 15.3% respectively excepting Brenner 
tumours.(34) We found that serous tumour accounted for (n=58) 
40.6% of all ovarian neoplasms, out of these (n=44) 75.9% were 
benign tumours, whereas (n=14 ) 24.1% were malignant ones (Table 
5).These findings are similar to the findings of Jha et al who found 
the serous tumour comprise (35.4%, 78.9%, 21.1% respectively) (32). 
These results were different to Elobied’s study (18.2%, 20.0% and 
80.0%respectively). (34) 
Serous cystadenoma in this study accounted for (n=44) 39.7% of all 
benign ovarian tumours (Table 7). This result is in agreement with 
Jha’s result 32.6%.(32) But it does not compare to in Yasmin’s, and 
Elobied’s studies 24.0%, 5.9% respectively.(35,34)  
Serous cystadenocarcinoma comprised (n=8) 25.0% of all malignant 
ovarian tumours (Table 8), whereas these figures were 46.2%, 
46.7%, 38.1% and 60.8%  in Jha, Wasim, Elobied and Dhakal 
respectively.(32,33,34,37) 
Borderline serous tumour accounted for (n=6) 4.2% for all ovarian 
neoplasms and (n=6) 18.8% of all malignant ones (Tables 5, 8). The 
latter result was only 2.1% of all malignant ones in Dhakal study. (35)    
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Similarly, mucinous tumours comprised (n=12) 8.4% of all ovarian 
neoplasms, out of these (n=11)91.7% were benign and (n=1) 8.3% 
were malignant (Table 5) in comparison with Jha’s study, in which 
the result were 16.8%, 77.8% and 22.2% respectively(32). But they 
were 27.2%, 73.3% and 26.7% in Elobied’s study respectively. (34) 
Mucinous cystadenoma in this study comprised (n=11) 9.9% of all 
benign ovarian neoplasms (Table 7). This result was agreement 
with Yasmin 11.5%.(35)  But it is different to Jha’s, Elobied’s results 
15.6%, 32.4% respectively.(32, 34)  
Endometroid carcinoma accounted in this study for (n=3) 9.4% of 
all malignant ovarian tumours (Table 8), as compared to Elobied 
and Yasmin 4.8% and 28.5% respectively.(34, 35)  
In this study germ cell tumours represented (n=52) 36.4% of all 
ovarian tumours (Table5) and this is similar to Elobied’s and Jha’s 
studies 36.4% and 42.2% respectively.(34, 32) 
Most germ cell tumours (n=48) 92.3% were benign and all of these 
benign germ cell tumours were mature cystic teratoma (Table 6). 
This figure was similar to Jha’s and Elobied’s studies 95.0% and 
95.6% respectively.(32,34) 
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Benign germ cell tumours comprised (n=48) 43.3% of all benign 
ovarian tumours, whereas malignant tumours constituted (n=4) 
12.5% of all malignant ones (Table 6). Similar figures had been 
found in Jha’s study 42.2% and 11.5% respectively. (32) But they are 
different to Elobied’s study 55.9% and 4.8%respectively. (34)  
Overall mature cystic teratoma was the most common tumour. This 
tumour in this study accounted for (n=46) 32.2% of all ovarian 
tumours and (n=46)41.4% of all benign ovarian tumours (Tables 5, 
7). Similar results were obtained by Jha 40.3% and 48.2%. (32) In spite 
of that Elobied’s study showed 34.5% and 55.9% (34), however, this 
figure is only 18.0% of all benign tumours in the study carried by 
Yasmins. (35)  
Immature teratomas were found in this study in (n=1) 2% of all 
teratoma and (n=1) 3.1% of all malignant ovarian tumours (Tables 
5, 8). But in the study carried out by Jha 4.4%, 7.7% and Elobied 
5.0% and 4.8% the percentages are higher. (32, 34) The latter figure 
was comparable 3.1% of all malignant ones in Dhakal’s study. 
Dysgerminoma constituted (n=2) 3.8% of all germ cell tumours and 
6.3% of all malignant ovarian tumours (Tables 5, 8). However, the 
 79
latter figure was only 3.1%, 14.3% of all malignant ovarian tumours   
in studies carried by Dhakal and Yasmin et al respectively. (37, 35)  
Sex cord-stromal tumours in this study comprised (n=14) 9.8% of 
all ovarian tumours (Table 5) in comparison to Elobied’s and Jha’s 
results 12.7%and3.1%respectively. (34, 32)  
Benign sex cord-stromal tumours formed (n=7)6.3% of all benign 
ovarian tumours, whereas malignant tumors made up (n=7) 21.9% 
of all malignant ones (Table 6). These results were compared with 
Jha 3.0% and 3.9%respectively. (32)  
Granulosa cell tumour accounted for (n=7) 4.9% of all ovarian 
tumours and (n=7) 21.9% of all malignant ones (Tables 5, 8). Studies 
carried out by Jha and Elobied showed 0.6%, 12.7% and 3.8%, 33.3% 
respectively.(32,34) The latter figure was 28.5%, 6.2 of all malignant 
ones in Yasmin’s and Dhakal’s studies. (35, 37)  
In this study thecoma and fibroma are benign sex cord tumors, 
comprised(n=4) 2.8% and (n=3) 2.1% of all ovarian tumours and 
3.6% and  2.7% of all benign tumours (Tables 5, 7), in comparison to 
Jha’s result 1.9% and 0.6% of all ovarian tumours and 2.2% and 
0.7% of all benign ones.(32)  
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Lymphoid tumours of the ovary and metastatic ones were far less 
common tumours. The lymphoid ones formed (n=1) 0.7% of all 
ovarian tumours and (n=1)3.1%of all malignant ones (Tables 5, 8). 
But the metastatic tumours of the ovary represented (n=1) 0.7% of 
all ovarian tumours and (n=1) 3.1% of all malignant ones (Tables 5, 
8). These figures were 3.6%, 9.5% and 2.5%, 15.4% for Elobied’s and 
Jha’s studies respectively.(34,32) The latter figure was  agreement 
with Dhakal’s study which is 5.2% of all malignant ones.(37)  
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CONCLUSION  
• Benign tumours were more common than malignant ones for all 
age groups.  
• The age of most ovarian tumours was between 21–30 years old.  
• Surface epithelial tumours were the most common class of ovarian 
tumours and germ cell tumours were next to it.  
• Benign surface epithelial tumours are the most common benign 
tumours and their malignant counterparts the most common 
malignant tumours.  
• Mature cystic teratoma was the most common ovarian tumours 
overall, as well as the most common benign tumour followed by 
serous cystadenoma. 
• Serous cystadenocarcinoma was the most common malignancy, 
followed by granulosa cell tumours. 
•  Malignant ovarian tumours were more common above the age of 
40 years. 
• The commonest presenting symptoms were lower abdominal pain 
and abdominal enlargement.     
•  In our study some data approximated to data from Nepal where 
as some approximated to Lahore (Pakistan).     
 82
RECOMMENDATIONS 
 
• Further in depth studies are highly recommended to be carried out 
for more evaluation of risk factors and to find out the causes for 
the high rate of the disease in this country.  
• For unnecessary removal of the ovary, frozen section is 
recommended.  
• Screening policy for ovarian cancer should be established for early 
detections.  
• Improvement of the cancer reporting and registration.  
• Detailed histopathological reporting, grading and staging.     
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Questionnaire 
A clinicopathological study in patients with ovarian neoplasms among 
Sudanese females  
 
 
Date: ....................................................................                              Serial No: ...........................................................           
Lab. No.: .................................................................                        Slide No: ...........................................................           
Name: ....................................................................                           Age: ...........................................................................           
Residence: .........................................................                         Phone No: ........................................................     
Tribe: ....................................................................                           Parity ...........................................................................           
Marital status:              - Single                - Married          
Family history:              - Yes                     - No      
Clinical remarks and duration:     
                              - Lower abdominal pain              - Abdominal swelling 
                              - Vaginal bleeding                         - Others      
Diagnosed by:     
                              - Imaging X ray                  - U/S                - CT scan 
                              - MRI                                   - Others   
Histopathology: 
• Type of specimens 
                              - Hysterectomy                             - Oophrectomy 
                              - Cystectomy                                 - Others      
Gross: .............................................................................................................................................................................................          
Microscopically: ...............................................................................................................................................................           
Diagnosis: .................................................................................................................................................................................           
Review/diagnosis: ..........................................................................................................................................................      
